Chewei Anderson Chang, Ethan Emberley, Aloma L D'Souza, Weilong Zhao, Cormac Cosgrove, Karen E Parrish, Diya Mitra, Elmer Payson, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Ryan Duggan, Cara Hrusch, Loren Lasko, Wissam Assaily, Pingping Zheng, Wei Liu, Axel Hernandez, Kimberley McCarthy, Zhaomei Zhang, Geunbae Rha, Zhensheng Cao, Yingchun Li, Olivia Perng, Jos Campbell, Gloria Zhang, Tyler Scott Curran, Milan Bruncko, Christopher C Marvin, Adrian D Hobson, Michael McPherson, Tamar Uziel, Marybeth A Pysz, Xi Zhao, Alexander Bankovich, Joel Hayflick, Michael McDevitt, Kevin J Freise, Susan Morgan-Lappe, James W Purcell
Glucocorticoids are key components of the current standard-of-care regimens (e.g., R-CHOP, EPOCH-R, Hyper-CVAD) for treatment of B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. CD19 displays restricted expression in normal B-cells and is up-regulated in B-cell malignancies. ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce glucocorticoid-associated toxicities while possessing three distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced Fc-mediated effector function via afucosylation of the antibody backbone...
May 3, 2024: Blood